政府新闻
迈威生物股价飙升，因中国生物科技公司达成价值高达10亿美元全球权益协议 2025-09-18
Shares of Mabwell Shanghai Bioscience jumped after the Chinese biotechnology company said it has signed a global licensing deal with a US firm for its pre-clinical heart drug for as much as USD1 billion.
Mabwell closed 13.2 percent higher at CNY54.75 (USD7.70) a share in Shanghai today, after opening up by its 20 percent exchange-imposed daily trading limit.
Under the deal, Kalexo Bio, a new company set up by US biotech investment fund Aditum Bio, will develop, manufacture, and commercialize 2MW7141 globally, the fund and Shanghai-based Mabwell announced separately yesterday.
2MW7141 is a novel dual-target siRNA candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease events. It was independently developed by Mabwell and is now in the pre-clinical trial stage.
“The formation of Kalexo Bio marks an important milestone for Mabwell as we expand the global reach of our innovative pipeline,” said Liu Datao, the Chinese firm’s founder, chairman, and chief executive.
“2MW7141 has shown compelling pre-clinical results, and we believe that through our partnership with Aditum Bio’s experienced team, we can accelerate its development and ultimately deliver a much-needed therapy to patients at risk of cardiovascular disease worldwide,” Liu noted.
“Cardiovascular disease remains the leading cause of death worldwide, and 2MW7141 represents a novel approach with the potential to change the standard of care in lipid management,” said Joe Jimenez, co-founder and managing director of Aditum Bio. “We are excited to partner with Mabwell and to launch Kalexo Bio as a dedicated company to advance this promising siRNA therapy into the clinic.”
Mabwell is eligible to receive up to USD1 billion from Kalexo Bio, including USD12 million in non-refundable upfront and near-term cash payments and milestone payments after 2MW7141 enters clinical trials and receives regulatory approval. Afterward, the firm will get low single-digit percentage royalties on global sales.
Mabwell will also receive a double-digit equity stake in Kalexo Bio if the product development progress meets the mutually agreed terms.
Aditum Bio is a biotech venture committed to improving health by accelerating drug development in disease areas with high unmet need where medical innovation can have a significant impact. It in-licenses promising drug candidates and spins out individual companies dedicated to bringing each candidate through early clinical trials.
Source: Yicai Global
